Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 for Children With Low-Grade Gliomas and Other Ras/Raf/ERK Pathway Activated Tumors
NCT02285439Phase 2Completed
- Sponsor
- Children's Hospital Los Angeles
- Start
- May 2016
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of binimetinib in glioma, malignant neoplasm and soft tissue neoplasm (STT) (3 arms), sponsored by Children's Hospital Los Angeles. Primary endpoints: Best Overall Response Rate at 48 weeks, Progression-Free Survival at 48 weeks and 1 more. Started May 2016; status: completed.
02
Drugs
binimetinib
03
Conditions
gliomamalignant neoplasmsoft tissue neoplasm (STT)
Beyond the preview
Go deeper on NCT02285439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285439.